Oregon Settlement Expands Disclosure Obligations Of Physicians Receiving Payments From Drug And Device Manufacturers

by Perkins Coie
Contact

As of August 1, 2013, pharmaceutical companies and medical device manufacturers are required to report to the federal government payments made to physicians under the Physician Payment Sunshine Act (PPSA).  The PPSA imposes no reporting requirements on the physicians who receive such payments; the reporting obligation rests only with the payor companies.  Moreover, such payments are not prohibited by the PPSA, but they will be compiled in a searchable data base and publicly available in the year following the payment.  A recent settlement by the Oregon Department of Justice (DOJ) goes far beyond the requirements of the PPSA in suggesting that physicians who receive payments from a medical device company have an obligation under the Oregon Unlawful Trade Practices Act (UTPA) to disclose the payments to patients in advance of treating patients with devices from the company.

Background Behind Oregon DOJ Settlement

The Oregon case involves two physicians who have entered into stipulated judgments with the Oregon DOJ to resolve allegations that they violated the UTPA by not informing patients that they were paid to train medical device salesmen while performing procedures to implant cardiac devices.  Medical device manufacturer Biotronik paid the physicians a training fee ranging from $400 - $1,250 per surgery when a trainee was present, which the state alleged violated the UTPA when the payment was not disclosed in advance to the patient.  According to media reports, Matthew Fedor, M.D. received more than $131,000 between 2007 and 2011 for training Biotronik employees during 257 surgeries, and  Kyong Turk, M.D. earned more than $97,000 between 2006 and 2009 for 126 surgeries.

Specifically, Oregon accused Drs. Fedor and Turk of having “misrepresented” their services as being “for the exclusive benefit of the patient” and “concealing” payments that created a potential “incentive” to use Biotronik defibrillators and pacemakers.  The state further alleged that Drs. Fedor and Turk “knew or should have known that these payments were something patients receiving Biotronik implants should know about, because they gave rise to an actual or potential conflict of interest that should have been disclosed.  [The doctors] also should have known that patients would want to know whether they were training subjects in a program to certify Biotronik sales representatives.” 

Under the stipulated judgments, each physician agreed to pay a $25,000 penalty and obtain written patient consent before receiving a payment from a drug or device manufacturer associated with that patient’s treatment.  The physicians also agreed not to permit any medical device salesperson who has not completed manufacturer training requirements to participate in surgeries without the patient’s written consent.  Finally, the physicians agreed to include a link on their practices’ websites to the PPSA payment database that will soon be available to the public, as required by Section 6002 of the Affordable Care Act.

New Enforcement Front Emerges on Physician Payments

Although the legal theories in the case remain untested, Oregon’s novel use of state consumer fraud laws may signal a new enforcement front in the crackdown on device and pharmaceutical manufacturer payments to physicians.  Here, a broadly worded consumer protection law was leveraged to extract civil fines and onerous affirmative disclosure obligations that far exceed what is specifically required by federal or state law. 

For example, under existing law, Biotronik is already required to disclose payments that Drs. Fedor and Turk receive for surgical training as of August 1, 2013 under the PPSA, and the payment data will be available to the public.  The state’s prosecution creates significant uncertainty, at least in Oregon, as to whether physicians can rely on PPSA payment reporting to defend against allegations about lack of transparency, and suggests that physicians may have to routinely disclose financial arrangements with third parties directly to patients in advance of treatment. 

 Practice Tips

  • The Oregon settlement should be a wake-up call for practitioners who receive payments from pharmaceutical or medical device manufacturers, particularly if, as in the Oregon case, payments are related to the number of procedures that are conducted. 
     
  • Practitioners should review with counsel the existing financial relationships they have with manufacturers to ensure the arrangements comply with applicable federal and state laws, including anti-kickback provisions.
     
  • Practitioners should also review existing practices with counsel to determine if affirmative disclosure of payments to patients may be optimal in order to minimize enforcement risk.
     
  • Although practitioners have no reporting obligation under the PPSA, they should communicate with pharmaceutical and device manufacturers to ensure the accuracy of the payment data that is being reported to the government.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Perkins Coie | Attorney Advertising

Written by:

Perkins Coie
Contact
more
less

Perkins Coie on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!